Quest Diagnostics Inc (DGX): Everett Cunningham , SVP, Commercial of Quest Diagnostics Inc sold 50,447 shares on May 6, 2016. The Insider selling transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were sold at $76.00 per share for a total value of $3,833,972.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 27, 2016, Catherine T. Doherty (SVP, Clin. Franchise Solutions) sold 29,550 shares at $74.43 per share price.On Mar 3, 2016, Michael E Prevoznik (SVP & General Counsel) sold 3,815 shares at $68.40 per share price.Also, On Aug 13, 2015, John C Md Baldwin (director) sold 2,266 shares at $72.00 per share price.On Aug 10, 2015, John B Ziegler (director) sold 2,200 shares at $74.35 per share price.
Quest Diagnostics Inc: On Friday, May 6, 2016 heightened volatility was witnessed in Quest Diagnostics Inc which led to swings in the share price. The shares opened for trading at $75.17 and hit $76 on the upside , eventually ending the session at $75.78, with a gain of 0.36% or 0.27 points. The heightened volatility saw the trading volume jump to 9,84,663 shares. The 52-week high of the share price is $89 and the company has a market cap of $10,720 M . The 52-week low of the share price is at $59.655.
Company has been under the radar of several Street Analysts.Quest Diagnostics Inc is Reiterated by RBC Capital Mkts to Sector Perform and the brokerage firm has raised the Price Target to $ 76 from a previous price target of $70 .The Rating was issued on Apr 22, 2016.Quest Diagnostics Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 75 from a previous price target of $72 .The Rating was issued on Apr 22, 2016.Quest Diagnostics Inc is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 84 from a previous price target of $75 .The Rating was issued on Apr 21, 2016.Quest Diagnostics Inc is Initiated by Credit Suisse to Neutral. The Rating was issued on Mar 16, 2016.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.